Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277316 · ClinicalTrials.gov registry record · Phase 2
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00277316: Clinical Trial Phase 2 study, sponsored by Symphony Evolution.
NCT00277316 is a Phase 2 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00277316, a Phase 2 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Why NCT00277316 stopped before completion
NCT00277316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00277316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00277316 about?
NCT00277316 is a clinical study titled "Study of XL999 in Patients With Metastatic Renal Cell Carcinoma". This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and ...
What is the current status of trial NCT00277316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00277316?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00277316?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00277316's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia